NDAINJECTIONSOLUTION
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug Shortage Active
NAROPIN is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
NAROPIN (ropivacaine hydrochloride) by Fresenius Kabi is s-(-)-enantiomer. First approved in 1996.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAROPIN (ropivacaine HCl) is an S-(-)-enantiomer local anesthetic administered by injection that blocks nerve impulse generation and conduction by increasing electrical threshold and slowing action potential propagation. It is used for regional anesthesia and pain management across surgical and non-surgical settings. The drug selectively blocks pain and temperature sensation before affecting touch, proprioception, and muscle tone.
LOE Approaching5mo to LOE
Product approaching loss of exclusivity with moderate competitive pressure (25/100) signals transition from growth to defensive positioning and potential team restructuring.
Mechanism of Action
S-(-)-enantiomer. Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Antalgic Efficacy of CycloMesh™ Soaked in Ropivacaine Hydrochloride in Uncomplicated Inguinal Hernia.
Started Oct 2019
304 enrolled
Inguinal Hernia
Why This Matters for Your Career
Worked on NAROPIN at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.